C-terminal Truncated Hepatitis B Virus X Protein is Associated with Metastasis and Enhances Invasiveness by C-Jun/matrix Metalloproteinase Protein 10 Activation in Hepatocellular Carcinoma
Overview
Affiliations
Unlabelled: Random integration of hepatitis B virus (HBV) DNA into the host genome is frequent in human hepatocellular carcinoma (HCC) and this leads to truncation of the HBV DNA, particularly at the C-terminal end of the HBV X protein (HBx). In this study, we investigated the frequency of this natural C-terminal truncation of HBx in human HCCs and its functional significance. In 50 HBV-positive patients with HCC, full-length HBx was detected in all nontumorous livers. However, full-length HBx was found in only 27 (54%) of the HCC tumors, whereas natural carboxylic acid (COOH)-truncated HBx was found in the remaining 23 (46%) tumors. Upon clinicopathological analysis, the presence of natural COOH-truncated HBx significantly correlated with the presence of venous invasion, a hallmark of metastasis (P = 0.005). Inducible stable expression of the COOH-truncated HBx protein (with 24 amino acids truncated at the C-terminal end) enhanced the cell-invasive ability of HepG2 cells, as compared to full-length HBx, using the Matrigel cell-invasion assay. It also resulted in increased C-Jun transcriptional activity and enhanced transcription of matrix metalloproteinase 10 (MMP10), whereas activation of the MMP10 promoter by COOH-truncated HBx was abolished when the activator protein 1-binding sites on the MMP10 promoter were mutated. Furthermore, silencing of MMP10 by short interfering RNA in HBxΔC1-expressing HepG2 cells resulted in significant reduction of cell invasiveness.
Conclusions: Our data suggest that COOH truncation of HBx, particularly with 24 amino acids truncated at the C-terminal end, plays a role in enhancing cell invasiveness and metastasis in HCC by activating MMP10 through C-Jun.
Expanding treatment indications in chronic hepatitis B: Should we treat all patients?.
Hui R, Mak L, Fung J, Seto W, Yuen M Hepatol Int. 2025; .
PMID: 39961977 DOI: 10.1007/s12072-025-10785-8.
Jeng L, Chan W, Teng C Cancer Control. 2025; 32:10732748251320492.
PMID: 39945469 PMC: 11826862. DOI: 10.1177/10732748251320492.
Applications of CRISPR/Cas as a Toolbox for Hepatitis B Virus Detection and Therapeutics.
Kumar A, Combe E, Mougene L, Zoulim F, Testoni B Viruses. 2024; 16(10).
PMID: 39459899 PMC: 11512240. DOI: 10.3390/v16101565.
Hepatitis B Viral Protein HBx: Roles in Viral Replication and Hepatocarcinogenesis.
Li D, Hamadalnil Y, Tu T Viruses. 2024; 16(9).
PMID: 39339838 PMC: 11437454. DOI: 10.3390/v16091361.
The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy.
Zhang M, Chen H, Liu H, Tang H Biomark Res. 2024; 12(1):84.
PMID: 39148134 PMC: 11328401. DOI: 10.1186/s40364-024-00611-y.